{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:03:44Z","timestamp":1785441824335,"version":"3.56.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ctrv.2025.102927","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T16:41:52Z","timestamp":1744303312000},"page":"102927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Primary testicular lymphoma"],"prefix":"10.1016","volume":"136","author":[{"given":"Brian T.","family":"Grainger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctrv.2025.102927_b0005","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.clon.2012.02.005","article-title":"Primary testicular lymphoma","volume":"24","author":"Ahmad","year":"2012","journal-title":"Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102927_b0010","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-10-530659","article-title":"Primary testicular lymphoma","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102927_b0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group","volume":"21","author":"Zucca","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102927_b0020","first-page":"3113","article-title":"Primary testicular lymphoma: a SEER analysis of 1,169 cases","volume":"17","author":"Xu","year":"2019","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102927_b0025","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2025.102927_b0030","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020911","article-title":"Primary large B-cell lymphomas of immune-privileged sites","author":"Roschewski","year":"2024","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102927_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164049","article-title":"Testicular diffuse large B-cell lymphoma-clinical, molecular, and immunological features","volume":"13","author":"Pollari","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"25","key":"10.1016\/j.ctrv.2025.102927_b0040","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ctrv.2025.102927_b0045","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102927_b0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PPO.0000000000000450","article-title":"Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma","volume":"26","author":"Roschewski","year":"2020","journal-title":"Cancer J"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102927_b0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.blre.2017.12.001","article-title":"The pathobiology of primary testicular diffuse large B-cell lymphoma: implications for novel therapies","volume":"32","author":"Twa","year":"2018","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102927_b0060","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/leu.2015.237","article-title":"Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium","volume":"30","author":"Deng","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102927_b0070","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102927_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpr.2022.300606","article-title":"Primary testicular follicular lymphoma","volume":"27","author":"Garces","year":"2022","journal-title":"Human Pathology Reports"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102927_b0080","doi-asserted-by":"crossref","first-page":"e0181","DOI":"10.1097\/MD.0000000000010181","article-title":"Primary testicular natural killer\/T-cell lymphoma: a CARE-case report and review of literature","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102927_b0085","first-page":"e4839","article-title":"A unique case of testicular plasmablastic lymphoma in a patient with human immunodeficiency virus","volume":"11","author":"Moazez","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102927_b0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0253-7184.156743","article-title":"Primary bilateral plasmablastic lymphoma of the testis in a human immunodeficiency virus positive man","volume":"36","author":"Badyal","year":"2015","journal-title":"Indian J Sex Transm Dis AIDS"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/CU9.0000000000000137","article-title":"Primary testicular lymphoma: clinical characteristics and oncological outcomes","volume":"17","author":"Medina","year":"2023","journal-title":"Curr Urol"},{"key":"10.1016\/j.ctrv.2025.102927_b0100","doi-asserted-by":"crossref","unstructured":"Alberto Artiles M, Javier Lorca \u00c1, In\u00e9s Laso G, et al. Testicular Lymphoma: Primary and Secondary Involvement. In: Yusuf T, ed. Lymphoma. Rijeka: IntechOpen; 2022: Ch. 5.","DOI":"10.5772\/intechopen.101505"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0105","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.critrevonc.2007.08.005","article-title":"Primary testicular lymphoma","volume":"65","author":"Vitolo","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102927_b0110","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.5858\/arpa.2010-0158-RS","article-title":"Primary diffuse large B-cell lymphoma of the testis","volume":"135","author":"Horne","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2025.102927_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2021.106519","article-title":"A case report of testicular diffuse large B-cell malignant lymphoma with cutaneous metastasis: a rare entity","volume":"88","author":"Hermi","year":"2021","journal-title":"Int J Surg Case Rep"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102927_b0120","first-page":"204","article-title":"Clinics in diagnostic imaging (134) Testicular lymphoma","volume":"52","author":"Srisuwan","year":"2011","journal-title":"Singapore Med J"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102927_b0125","first-page":"121","article-title":"Testicular malignant lymphoma; imaging and diagnosis","volume":"14","author":"Emura","year":"1996","journal-title":"Radiat Med"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2025.102927_b0130","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1439-0272.2011.01236.x","article-title":"Primary diffuse large B-cell testicular lymphoma: magnetic resonance imaging findings","volume":"44","author":"Tsili","year":"2012","journal-title":"Andrologia"},{"key":"10.1016\/j.ctrv.2025.102927_b0135","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19686","article-title":"Central nervous system prophylaxis in large B-cell lymphoma: a British Society for Haematology Good Practice Paper","author":"Wilson","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102927_b0140","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019463","article-title":"Primary testicular diffuse large B-cell lymphoma: case series","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102927_b0145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pathol.2019.08.013","article-title":"Diffuse large B-cell lymphoma variants: an update","volume":"52","author":"Sukswai","year":"2020","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102927_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12308-023-00556-5","article-title":"\u201cQuadruple-hit\u201d primary testicular diffuse large B-cell lymphoma with MYD88 L265P mutation, IGH::MYC, and IRF4- and BCL6-rearrangements","volume":"16","author":"Bruehl","year":"2023","journal-title":"J Hematop"},{"issue":"13","key":"10.1016\/j.ctrv.2025.102927_b0155","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/bloodadvances.2019000251","article-title":"COO and MYC\/BCL2 status do not predict outcome among patients with stage I\/II DLBCL: a retrospective multicenter study","volume":"3","author":"Barraclough","year":"2019","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.ctrv.2025.102927_b0160","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ctrv.2025.102927_b0165","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1200\/JCO.2009.22.5896","article-title":"Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab","volume":"27","author":"Gundrum","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102927_b0170","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ajh.21522","article-title":"Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement","volume":"84","author":"Go","year":"2009","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102927_b0175","first-page":"1541","article-title":"IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma","volume":"8","author":"Conconi","year":"2024","journal-title":"BloodAdv"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102927_b0180","article-title":"Age related differences in primary testicular lymphoma: A population based cohort study","volume":"41","author":"Berjaoui","year":"2023","journal-title":"Urologic Oncol: Seminars Original Investigations"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102927_b0185","doi-asserted-by":"crossref","first-page":"3075-","DOI":"10.1182\/blood-2024-198325","article-title":"The impact of MYD88 and\/or CD79B gene mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma","volume":"144","author":"Suzuki","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102927_b0190","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood.2020006338","article-title":"Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma","volume":"137","author":"Twa","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102927_b0195","first-page":"123","article-title":"The management and treatment of primary testicular lymphoma","volume":"8","author":"Castellino","year":"2014","journal-title":"Hematol Educ: Educ Program Ann Cong Eur Hematol Assoc"},{"issue":"suppl 5","key":"10.1016\/j.ctrv.2025.102927_b0200","doi-asserted-by":"crossref","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","article-title":"Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Vitolo","year":"2016","journal-title":"Ann Oncol"},{"issue":"10216","key":"10.1016\/j.ctrv.2025.102927_b0205","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.102927_b0210","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2023-186261","article-title":"Favourable outcome of abbreviated R-CHOP in patients with primary testicular lymphoma","volume":"142","author":"Al-Sarayfi","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3816\/CLM.2001.n.016","article-title":"Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors","volume":"2","author":"Seymour","year":"2001","journal-title":"Clin Lymphoma"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0220","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.14392","article-title":"Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era","volume":"176","author":"Kridel","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102927_b0225","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","article-title":"First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial","volume":"29","author":"Vitolo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102927_b0230","doi-asserted-by":"crossref","first-page":"1724-","DOI":"10.1182\/blood-2024-194482","article-title":"A pilot study of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (VIPOR) for diffuse large B-cell lymphoma involving the central nervous system","volume":"144","author":"Dalela","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0235","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijrobp.2012.06.019","article-title":"Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study","volume":"85","author":"Brouwer","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2025.102927_b0240","article-title":"NCCN guidelines on B-cell lymphomas, version 3.2024","author":"Zelenetz","year":"2024","journal-title":"NCCN Clin Practice Guidelines Oncol"},{"issue":"35","key":"10.1016\/j.ctrv.2025.102927_b0245","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1200\/JCO.23.00365","article-title":"High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma","volume":"41","author":"Lewis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102927_b0250","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"CancerDiscov"},{"key":"10.1016\/j.ctrv.2025.102927_b0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102927_b0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102927_b0265","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2643-3230.BCD-21-0063","article-title":"Overcoming acquired epigenetic resistance to BTK inhibitors","volume":"2","author":"Shaffer","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102927_b0270","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102927_b0275","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","article-title":"Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma","volume":"69","author":"Hottinger","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ctrv.2025.102927_b0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","article-title":"Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma","volume":"93","author":"El-Galaly","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0285","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","article-title":"MATRix\u2013RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial","volume":"8","author":"Ferreri","year":"2021","journal-title":"Lancet Haematol"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102927_b0290","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102927_b0295","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2024-199702","volume":"144","author":"Ahmed","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102927_b0300","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2022-165256","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed\/refractory primary and secondary central nervous system lymphoma (CNSL)","volume":"140","author":"Jacobson","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102927_b0305","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102927_b0310","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102927_b0315","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.ctrv.2025.102927_b0320","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102927_b0325","doi-asserted-by":"crossref","first-page":"3751-","DOI":"10.1182\/blood-2024-209383","article-title":"Outcomes of chimeric antigen receptor (CAR) T-cell therapy in extranodal (EN) B-cell non-hodgkin lymphoma (NHL): results from a multicenter analysis","volume":"144","author":"St-Pierre","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0330","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102927_b0335","first-page":"978","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"LancetOncol"},{"issue":"24","key":"10.1016\/j.ctrv.2025.102927_b0340","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102927_b0345","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102927_b0350","first-page":"e511","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"LancetHaematol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102927_b0355","first-page":"1629","article-title":"Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma","volume":"6","author":"Yang","year":"2022","journal-title":"BloodAdv"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102927_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.ctrv.2025.102927_b0365","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.2020006784","article-title":"Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2025.102927_b0370","first-page":"1595","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"BloodAdv"},{"issue":"21","key":"10.1016\/j.ctrv.2025.102927_b0375","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102927_b0380","first-page":"9489","article-title":"Primary testicular lymphoma with central nervous system relapse was successfully treated by a chemo-free regimen: a case report and literature review","volume":"13","author":"Yan","year":"2021","journal-title":"CancerManag Res"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102927_b0385","doi-asserted-by":"crossref","first-page":"4-","DOI":"10.1182\/blood-2020-138924","article-title":"Nivolumab in primary CNS lymphoma and primary testicular lymphoma with CNS involvement: single center experience","volume":"136","author":"Gavrilenko","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102927_b0390","unstructured":"A study of nivolumab in relapsed\/refractory primary central nervous system lymphoma (PCNSL) and relapsed\/refractory primary testicular lymphoma (PTL) (CheckMate 647). [Accessed December 1, 2024]. clinicaltrials.gov; 2023."},{"issue":"11","key":"10.1016\/j.ctrv.2025.102927_b0395","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102927_b0400","doi-asserted-by":"crossref","first-page":"139","DOI":"10.21873\/cdp.10192","article-title":"Primary testicular lymphoma: single center experience","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Diagn Progn"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102927_b0405","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/16078454.2022.2119345","article-title":"Characteristic features of primary testicular lymphoma and survival trends: a multicenter clinical study","volume":"27","author":"Sun","year":"2022","journal-title":"Hematology"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:27:00Z","timestamp":1762291620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":81,"alternative-id":["S0305737225000490"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102927","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary testicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102927"}}